Sol-gel Technologies Ltd. · NASDAQ:SLGL
Sol-gel Technologies — Investor Presentation (June 2018)
17 slides from Sol-gel Technologies's investor presentation, Jun 6, 2018
Slide 1: Company and Products Overview | June 2018
NASDAQ: SLGL Company and Products Overview | June 2018
Slide 2: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements This document contains forward-looking statements of Sol-Gel Technologies Ltd. (the ‘COMPANY’). All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of oper
Slide 3: Our Dermatology Company
Our Dermatology Company Branded and generic clinical-stage pipelines of topical drugs Proprietary microencapsulation delivery system Phase II clinical data on three branded drug product candidates Four collaborations on generic products with 50/50 gross profit sharing Tentative approval for our 1 st
Slide 4: Our Branded and Generic Pipelines
Our Branded and Generic Pipelines Program Research Preclinical Phase II Phase III Filed TWIN acne vulgaris SIRS-T Based on TWIN Phase II EpsolayR (VERED) Program Research Bioequivalence Filed subtype II rosacea Ivermectin Tentative approval cream, 1% as of January 29, 2018 Generic candidate # 2 Comp
Slide 5: Common Indications Requiring Better Therapies
Common Indications Requiring Better Therapies A disease of the pilosebaceous unit, involving abnormalities in sebum production, follicular epithelial desquamation, bacterial proliferation and inflammation Benzoyl peroxide, tretinoin, adapalene and topical antibiotics are the mainstay of acne therapi
Slide 6: Our Branded Drug Product Candidates
Our Branded Drug Product Candidates Designed to be a highly effective treatment for acne vulgaris by combining benzoyl peroxide and tretinoin TWIN Major challenges were the instability of tretinoin in the presence of benzoyl peroxide and irritation (acne vulgaris) Encapsulation allows stabilization
Slide 7: Our Microencapsulation Platform
Our Microencapsulation Platform Encapsulated tretinoin microcapsule Encapsulated tretinoin crystals inside broken microcapsule SEM pictures of our silica-based encapsulated tretinoin Company and Products Overview | June 2018 7
Slide 8: TWIN Phase II Co-Primary Efficacy Results (ITT)
TWIN Phase II Co-Primary Efficacy Results (ITT) Success in Dichotomized IGA at Week 12 P-value vs. vehicle 0.006 <0.001 0.015 0.001 50% 39.7% 40% 31.7% 27.4% 30% 24.9% 22.1% 20% 12.3% 10% N=115 N=116 N=117 N=118 N=118 N=118 0% Vehicle TWIN TWIN E-ATRA E-ATRA E-BPO Low High Low High Inflammatory Lesi
Slide 9: SIRS-T Supportive Clinical Results (ITT)
SIRS-T Supportive Clinical Results (ITT) Success in Dichotomized IGA at Week 12 P-value vs. vehicle 0.015 0.001 50% 40% 31.7% 30% 24.9% 20% 12.3% 10% N=115 N=118 N=118 0% Vehicle E-ATRA E-ATRA Low High Inflammatory Lesion Mean Percent Change from Baseline at Week 12 Non-Inflammatory Lesion Mean Perc
Slide 10: Epsolay Phase II Co-Primary Efficacy Results (ITT)
EpsolayR Phase II Co-Primary Efficacy Results (ITT) Success in Dichotomized IGA at Week 12 Inflammatory Lesion Count Change from Baseline at Week 12 P-value vs. vehicle 0.0013 Vehicle E-BPO 1% EpsolayR 5% 0 TheFDArequiredamodificationtoourdefinitionof”clear”ontheIGAscalesuchthatthecategory of “clear
Slide 11: Other Acne Trial Results
Other Acne Trial Results (‡) Moderate Patients (ITT) TWIN Phase II Epiduo ForteR Phase III AczoneR Phase III (Trial 006) 31.3% 25.2% Success in IGA 9.0% at Week 12 TWIN High Epiduo Forte Aczone (Moderate Patients) (Moderate Patients) 7.5% Inflammatory Lesions Mean 22.1% 17.9% Percent Change 6.7% fro
Slide 12: Other Subtype II Rosacea Trial Results (ITT)
Other Subtype II Rosacea Trial Results (‡) (ITT) EpsolayR SoolantraR FinaceaR Foam MetrogelR OraceaR Phase II (1) Phase III Phase III Phase III (2) Phase III (3) 33.3% 26.8% 21.3% Success in IGA at Week 12 10.9% 10.9% 11.3% 8.7% 8.5% EpsolayR SoolantraR SoolantraR FinaceaR Foam FinaceaR Foam Metroge
Slide 13: Our Upcoming Phase III Pivotal Trials
Our Upcoming Phase III Pivotal Trials SPA request was submitted and we have an agreement in place on the study design Each pivotal trial is planned to enroll 350 subjects in a 2:1 ratio of EpsolayR 5% vs. vehicle, with a EpsolayR power > 99% Pivotal trials are planned to be initiated in H1/2018 with
Slide 14: Our Generic Pipeline
Our Generic Pipeline Six generic drug candidates in our pipeline; some are being developed before Broad Pipeline the reference listed drug (RLD) is approved; one received tentative approval Three of our generic drug product candidates are being developed in Multiple Partnerships collaboration with P
Slide 15: Financial Profile
Financial Profile Gross proceeds of $86.3 million raised in IPO of 7,187,500 ordinary shares on February 5, 2018 18,949,968 shares outstanding as of March 31, 2018 $83.8 million of cash, cash equivalents and deposits as of March 31, 2018 Cash runway expected to be sufficient to fund Phase III clinic
Slide 16: Recent Milestones and Next Steps
Recent Milestones and Next Steps 2017 2018 2019 Reported positive results from TWIN Obtained tentative approval of ANDA Plans to report Phase III results for PhaseIItrialinacnevulgaris for ivermectin cream, 1% (sponsored TWINinacnevulgaris byPerrigo) Had an EOPII meeting with the FDA Plans to report
Slide 17: For further information please contact
For further information please contact alon.seri-levy@sol-gel.com
Sol-Gel Technologies — Investor Presentation (June 2018) on 6ix